EVGN Quote, Financials, Valuation and Earnings

Compugen Ltd. has a net margin of -874.68% compared to Evogene Ltd.'s net margin of -369.06%. Evogene Ltd.'s return on equity of -66.95% beat Compugen Ltd.'s return on equity of -51.8%.

Evogene Ltd. has a consensus price target of $2.50, signalling upside risk potential of 145.1%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 239.18%. Given that Compugen Ltd. has higher upside potential than Evogene Ltd., analysts believe Compugen Ltd. is more attractive than Evogene Ltd..

Evogene Ltd. has a beta of 1.352, which suggesting that the stock is 35.162% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.864, suggesting its more volatile than the S&P 500 by 186.386%.

Evogene Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evogene Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.

Evogene Ltd. quarterly revenues are $312K, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. Evogene Ltd.'s net income of -$2.7M is higher than Compugen Ltd.'s net income of -$7M. Notably, Evogene Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evogene Ltd. is 1.43x versus 22.85x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

MediWound Ltd. has a net margin of -874.68% compared to Evogene Ltd.'s net margin of -48.85%. Evogene Ltd.'s return on equity of -66.95% beat MediWound Ltd.'s return on equity of -61.71%.

Evogene Ltd. has a consensus price target of $2.50, signalling upside risk potential of 145.1%. On the other hand MediWound Ltd. has an analysts' consensus of $31.50 which suggests that it could grow by 82.61%. Given that Evogene Ltd. has higher upside potential than MediWound Ltd., analysts believe Evogene Ltd. is more attractive than MediWound Ltd..

Evogene Ltd. has a beta of 1.352, which suggesting that the stock is 35.162% more volatile than S&P 500. In comparison MediWound Ltd. has a beta of 0.133, suggesting its less volatile than the S&P 500 by 86.712%.

Evogene Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MediWound Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evogene Ltd. pays -- of its earnings as a dividend. MediWound Ltd. pays out -- of its earnings as a dividend.

Evogene Ltd. quarterly revenues are $312K, which are smaller than MediWound Ltd. quarterly revenues of $5.4M. Evogene Ltd.'s net income of -$2.7M is lower than MediWound Ltd.'s net income of -$2.7M. Notably, Evogene Ltd.'s price-to-earnings ratio is -- while MediWound Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evogene Ltd. is 1.43x versus 8.95x for MediWound Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Nano-X Imaging Ltd. has a net margin of -874.68% compared to Evogene Ltd.'s net margin of -396.98%. Evogene Ltd.'s return on equity of -66.95% beat Nano-X Imaging Ltd.'s return on equity of -32.75%.

Evogene Ltd. has a consensus price target of $2.50, signalling upside risk potential of 145.1%. On the other hand Nano-X Imaging Ltd. has an analysts' consensus of $7.40 which suggests that it could grow by 230.36%. Given that Nano-X Imaging Ltd. has higher upside potential than Evogene Ltd., analysts believe Nano-X Imaging Ltd. is more attractive than Evogene Ltd..

Evogene Ltd. has a beta of 1.352, which suggesting that the stock is 35.162% more volatile than S&P 500. In comparison Nano-X Imaging Ltd. has a beta of 1.312, suggesting its more volatile than the S&P 500 by 31.211%.

Evogene Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nano-X Imaging Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evogene Ltd. pays -- of its earnings as a dividend. Nano-X Imaging Ltd. pays out -- of its earnings as a dividend.

Evogene Ltd. quarterly revenues are $312K, which are smaller than Nano-X Imaging Ltd. quarterly revenues of $3.4M. Evogene Ltd.'s net income of -$2.7M is higher than Nano-X Imaging Ltd.'s net income of -$13.7M. Notably, Evogene Ltd.'s price-to-earnings ratio is -- while Nano-X Imaging Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evogene Ltd. is 1.43x versus 11.49x for Nano-X Imaging Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Pluri, Inc. has a net margin of -874.68% compared to Evogene Ltd.'s net margin of -1940.51%. Evogene Ltd.'s return on equity of -66.95% beat Pluri, Inc.'s return on equity of -5662.45%.

Evogene Ltd. has a consensus price target of $2.50, signalling upside risk potential of 145.1%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 220.86%. Given that Pluri, Inc. has higher upside potential than Evogene Ltd., analysts believe Pluri, Inc. is more attractive than Evogene Ltd..

Evogene Ltd. has a beta of 1.352, which suggesting that the stock is 35.162% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.181%.

Evogene Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evogene Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.

Evogene Ltd. quarterly revenues are $312K, which are smaller than Pluri, Inc. quarterly revenues of $316K. Evogene Ltd.'s net income of -$2.7M is higher than Pluri, Inc.'s net income of -$6.1M. Notably, Evogene Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evogene Ltd. is 1.43x versus 20.45x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.